Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Beimei Pharma In-licenses Acne Therapy from Sol-Gel in $15 Million Deal

publication date: May 16, 2024

Shenzhen Beimei Pharma acquired greater China rights for Twyneo®, a therapy for acne vulgaris, from Israel’s Sol-Gel for $15 million. Sol-Gel will be eligible to receive up to $10 million in upfront and regulator milestones. The remaining $5 million is potential royalty payments. Twyneo is the only fixed-dose combination of tretinoin and benzoyl peroxide cream available in the US; it is approved to treat acne vulgaris in adults and pediatric patients. Beimei markets products for pediatrics patients with a portfolio of more than 40 drugs approved or in the pipeline. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here